xRead - September 2022

Wise et al.

Page 170

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Nothing to disclose

Author

Company

Nature of relationship

Guidotti-Malesci

Research or speaker or advisory

Glaxo Smith Kline

Research or speaker or advisory

HAL Allergy

Research or speaker or advisory

MEDA

Research or speaker or advisory

Merck

Research or speaker or advisory

Merck Sharp & Dome

Research or speaker or advisory

Novartis

Research or speaker or advisory

Recordati-InnuvaPharma

Research or speaker or advisory

Roche

Research or speaker or advisory

Sanofi-Aventis

Research or speaker or advisory

Stallergenees

Research or speaker or advisory

UCB Pharma

Research or speaker or advisory

Uriach Pharma

Research or speaker or advisory

Teva

Research or speaker or advisory

Thermo Fisher

Research or speaker or advisory

Valeras

Research or speaker or advisory

Vibor-Pharma

Research or speaker or advisory

Thomas Chacko, MD

X

Cemal Cingi, MD

X

Giorgio Ciprandi, MD

Stallergenes

Consultant

Jacquelynne Corey, MD

Greer-Stallergenes

Consultant, speaker’s bureau

CSL

Advisory board

Behring

Advisory board

Intersect ENT

Advisor

Linda S. Cox, MD

X

Peter Socrates Creticos, MD

Stellergenes-Greer

Research funding, consultant

Circassia

Research funding, consultant

ASIT: Allergy therapeutics

Consultant

Merck

Research funding

National Institute of Allergy and Infectious Diseases Patient-Centered Outcomes Research Institute

Research funding

Research funding

Adnan Custovic, MSc, DM, MD, PhD

Novartis

Consultant

Boehringer Ingelheim

Consultant

ALK-Abello

Consultant

Thermo Fisher

Speaker

Glaxo Smith Kline

Speaker

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.